Human Hybridoma Cells
Human Hybridoma Cells are a cornerstone of modern biotherapeutics and immunology, created by the strategic fusion of human B lymphocytes with suitable myeloma partner lines. Unlike murine models, these human-derived systems are essential for generating fully human monoclonal antibodies (mAbs), significantly reducing the risks of immunogenicity in clinical applications.
Our comprehensive collection of human hybridoma cell lines offers stable and efficient platforms for antibody discovery. These lines are widely utilized in the development of targeted cancer therapies, the study of autoimmune disease mechanisms, and the production of highly specific reagents for advanced diagnostic assays such as ELISA and flow cytometry.
Fully Human Origin Stable Secretion High Specificity Clinical Relevance
Key Features & Research Applications
Our human hybridoma cell lines are engineered to meet the rigorous demands of biopharmaceutical and academic research:
Optimized Antibody Production
- Established from robust fusion partners to ensure limitless proliferation and high-titer antibody secretion.
- Consistent production of homogenized antibodies with uniform affinity and specificity.
- Suitable for both small-scale laboratory research and scalable in vitro production workflows.
Therapeutic & Diagnostic Power
- Primary tool for generating therapeutic Grade mAbs with low HAMA (Human Anti-Mouse Antibody) response.
- Applications in Infectious Disease research, including neutralizing antibody studies for viruses and bacteria.
- Ideal for identifying novel tumor-associated antigens and clinical biomarkers.
Rigorous Quality Standards
- Verified through STR profiling and isoenzyme analysis to confirm human origin and clonal purity.
- Strictly screened for Mycoplasma, EBV, and other adventitious agents to ensure safety.
- Cryopreserved at low passage to maintain phenotypic stability and secretory function.
FAQ
What are the advantages of human hybridomas over mouse hybridomas?
Human hybridomas produce fully human antibodies, which are essential for clinical applications as they minimize the risk of immune rejection (immunogenicity) that often occurs with mouse-derived antibodies when used in patients.
How stable is the antibody secretion in these cell lines?
Our human hybridoma lines are selected for their long-term stability. While some hybridomas can experience chromosome loss over time, we provide low-passage cells and optimized culture protocols to ensure consistent antibody production.
Can these cell lines be used for antibody sequencing and engineering?
Yes. These lines are excellent starting points for antibody sequencing (NGS), allowing researchers to clone the variable regions for further recombinant reformatting, such as humanization or Fc-engineering.
What are the recommended culture conditions for high antibody yields?
Most human hybridomas thrive in enriched media like RPMI 1640 or DMEM supplemented with 10-15% high-quality FBS. For maximum yield, we recommend maintaining cells in their exponential growth phase and monitoring nutrient levels regularly.